# A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

> **NCT01000818** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 18 (actual)

## Conditions studied

- HIV-1 Infection
- HIV Infections

## Interventions

- **DRUG:** MK0518 (Raltegravir)
- **DRUG:** famotidine
- **DRUG:** omeprazole

## Key facts

- **NCT ID:** NCT01000818
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000818, "A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01000818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*